Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD

Wickremasinghe, Sanjeewa S., Busija, Lucy, Guymer, Robyn H., Wong, Tien Y. and Qureshi, Salmaan 2012, Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD, Investigative ophthalmology & visual science, vol. 53, no. 1, pp. 37-41, doi: 10.1167/iovs.11-7689.

Attached Files
Name Description MIMEType Size Downloads

Title Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD
Author(s) Wickremasinghe, Sanjeewa S.
Busija, Lucy
Guymer, Robyn H.
Wong, Tien Y.
Qureshi, Salmaan
Journal name Investigative ophthalmology & visual science
Volume number 53
Issue number 1
Start page 37
End page 41
Total pages 5
Publisher Association for Research in Vision and Ophthalmology
Place of publication [St Louis, Mo.]
Publication date 2012-01
ISSN 0146-0404
Keyword(s) eyes
neovascular AMD
intravitreal ranibizumab
age-related vascular degeneration
Summary Purpose
To examine whether baseline retinal vascular caliber predicts visual response to intravitreal ranibizumab injections in patients with neovascular age-related macular degeneration (AMD).

In this prospective cohort study, patients with neovascular AMD received three monthly intravitreal injections of ranibizumab, followed by as needed dosing up to 1 year. Retinal vascular caliber was measured from digital fundus photographs at baseline and summarized as central retinal artery equivalent (CRAE) and venular equivalent (CRVE), representing average caliber of arterioles and venules, respectively. Visual outcome at 12 months was assessed and the relation to baseline retinal vascular caliber was determined.

A total of 88 eyes were analyzed at baseline. After accounting for age, sex, size of choroidal neovascularization, and number of injections, patients who deteriorated in visual acuity at 12 months had significantly larger baseline CRVE, 243.10 μm (95% confidence interval [CI], 227.01–259.19), compared with those who were stable, 214.30 μm (95% CI, 205.79–222.81) and those who improved, 215.26 μm (95% CI, 204.69–225.84; P = 0.007). Baseline CRAE did not differ significantly from eyes whose vision deteriorated, 150.12 μm (95% CI, 140.67–159.57), compared with those remaining stable, 143.64 μm (95% CI, 138.64–148.63), or gaining vision 142.92 μm (95% CI, 136.71–149.13; P = 0.69).

In eyes with neovascular AMD treated with intravitreal ranibizumab, larger baseline retinal venular caliber was significantly associated with a poorer response to treatment, possibly reflecting increased disease severity.
Language eng
DOI 10.1167/iovs.11-7689
Field of Research 111301 - Ophthalmology
Socio Economic Objective 920107 - Hearing, Vision, Speech and Their Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2012, Association for Research in Vision and Ophthalmology
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
PVC's Office - Health
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 169 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Mon, 10 Mar 2014, 14:52:49 EST by Lucy Busija

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact